Martin David Harp

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

A look back at some of the biggest stories in ophthalmology in 2023.

David Hutton of Ophthalmology Times talks with Jay Katz, MD, CMO for Glaukos, and Steven R. Sarkisian, MD, about the Glaukos iDose travoprost implant.

Viridian's VRDN-003, a subcutaneous therapy for thyroid eye disease, has demonstrated positive data in a Phase 1 clinical study, with an extended half-life of 40-50 days. The company plans to initiate global pivotal trials in mid-2024, aiming to transform TED treatment with less frequent dosing intervals.

Eric Jennings, MD, from Woolfson Eye Institute, discusses the SMARTCataract cloud-based app from Alcon and its implementation where he practices with David Hutton, Managing Editor, Ophthalmology Times.

LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.

Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.

The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.

TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and s being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.

The company says top-line efficacy and safety data is on track for release in December of 2023.

Sanjib Kumar Kar, MBBS, MD, was caught taking a bribe of ₹5,500 (~$65 USD) from a complainant to conduct surgery on his uncle.

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).

Physician details her journey from sustaining career-ending injury to insurance advocate.

Air quality across Delhi has been in the “very poor” category, with AQI ranging from 350 to a severe rating of 450.

Flinders University Ophthalmologists have devised a novel glaucoma polygenic risk score (PRS) that identifies those at high risk of losing their sight and prioritizes their treatment.

A study of the course was conducted in Vietnam, and showed participant scores doubled following the online course, to a level like local ophthalmologists.

This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

The week focuses on bringing awareness to TED through emphasis on mental health and art therapy solutions.

Nearly 75% of patients suffered eye infections following the event.

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

AMDX-2011P aims to revolutionize glaucoma detection with micron-level amyloid beta tracking.

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).

Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint.

Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.

Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

Eight patients were able to receive a second implant at 21 weeks, with no product related adverse effects.